Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia

Sanofi announced that its drug Wayrilz (rilzabrutinib), a BTK inhibitor, has received marketing authorization in Japan for treating persistent or chronic immune thrombocytopenia (ITP) in patients who don't respond to other treatments. The approval is based on the LUNA 3 phase 3 study, which demonstrated rapid and durable platelet response and improved quality of life compared to placebo.